Table 5 “Concomitant LABA and ICS users” stratified by inhaler type for the years 2004 to 2008: “Combined Inhalers”, “Separate Inhalers”, “Combinations”
From: Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
Year | |||||
|---|---|---|---|---|---|
2004 | 2005 | 2006 | 2007 | 2008 | |
Combined inhalers [fixed LABA/ICS] | 101,814 (82.2%) | 126,347 (82.7%) | 126,301 (82.9%) | 145,464 (84.5%) | 151,784 (85.7%) |
Separate inhalers [non-fixed LABA/ICS] | 15,044 (12.1%) | 18,490 (12.1%) | 17,767 (11.7%) | 17,930 (10.4%) | 16,750 (9.5%) |
Combinations | 7,015 (5.7%) | 8,020 (5.2%) | 8,350 (5.5%) | 8,831 (5.1%) | 8,625 (4.9%) |